Citations

Clear

4847 citation(s) found for "Yu, Eric".

Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma
Malikowski, Thomas, Levy, Michael J. , Gleeson, Ferga C. , Topazian, Mark , Iyer, Prasad G. , Rajan, Elizabeth , Roberts, Lewis R. , Abu Dayyeh, Barham K, Roberts, Lewis R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | December 20, 2019 | Volume: 72 | Issue: 3 | Pages: 940-948

10.1002/hep.31077 | PMID 31860935 Get It

Background and Aims Presence of malignant regional lymph nodes (MRLNs) precludes curative oncological resection or liver transplantation for cholangiocarcinoma (CCA). Limited data support the utility of endoscopic ultrasound (EUS)/fine needle aspiration (FNA) for detection of MRLNs in extrahepatic CCA, but there are no data for its role in intrahepatic CCA (iCCA). The aim of this study is to evaluate the staging impact of EUS for CCA, including analysis by subtype. Approach and Results We identified consecutive patients with CCA who underwent EUS staging at a single tertiary care center from October 2014 to April 2018. Among this cohort, we abstracted clinical demographic, radiographical, procedural, cytopathological, and surgical data. STATA 15 software was used for comparative analysis calculations (StataCorp LP, College Station, TX). The study cohort included 157 patients; 24 (15%), 124 (79%), and 9 (6%) with intrahepatic, perihilar, and distal CCA, respectively. EUS was able to identify regional lymph nodes (RLNs) in a higher percentage of patients compared to cross‐sectional imaging (86% vs. 47%; P < 0.001). FNA was performed in 133 (98.5%) patients with RLNs, with a median of three passes per node. EUS‐FNA identified MRLN in 27 of 31 (87.1%) patients ultimately found to have MRLNs. For iCCA, EUS detected a higher percentage of RLN compared to cross‐sectional imaging (83% vs. 50%; P = 0.048), with MRLNs identified in 4 (17%) patients. Among the entire cohort, identification of at least one MRLN by EUS was associated with lower median survival (353 vs. 1,050 days; P < 0.001) and increased risk of death (hazard ratio = 4.1; P < 0.001). Conclusions EUS‐FNA is effective for identifying MRLN in patients with CCA, and should be routinely incorporated into staging of all CCA subtypes given the impact of MRLN on prognosis and management decisions.
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Vaubel, Rachael A. , Tian, Shulan , Remonde, Dioval , Mladek, Ann C. , Kitange, Gaspar J. , Caron, Alissa, Kollmeyer, Thomas M. , Grove, Rebecca, Peng, Sen, Carlson, Brett L. , Sarkar, Gobinda , Evers, Lisa, Decker, Paul A. , Yan, Huihuang , Berens, Michael E. , Wang, Qianghu , Marin, Bianca M. , Klee, Eric W. , Eckel‐Passow, Jeanette E. , Verhaak, Roel G.W. , Sulman, Erik P. , Meyer, Fredrick B., Tran, Nhan L. , Jenkins, Robert B. , Schroeder, Mark A. , Sarkar, Gobinda , Berens, Michael E , Wang, Qianghu , Marin, Bianca M , Califano, Andrea , Sulman, Erik P , O'Neill, Brian P, Parney, Ian F , Kollmeyer, Thomas , Vaubel, Rachael A , Mladek, Ann C , Tran, Nhan L , Grove, Rebecca, Daniel, J. , Decker, Paul A. , Dhruv, Harshil , Lachance, Daniel Honore , Burns, Terry C. , O’Neill, Brian Patrick , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

Clinical Cancer Research | December 18, 2019 | Volume: 26 | Issue: 5 | Pages: 1094-1104

10.1158/1078-0432.ccr-19-0909 | PMID 31852831 Get It

Abstract Purpose: Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization. Experimental Design: PDXs were established from glioblastoma, IDH-wildtype (n = 93), glioblastoma, IDH-mutant (n = 2), diffuse midline glioma, H3 K27M-mutant (n = 1), and both primary (n = 60) and recurrent (n = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, n = 83), RNA-sequencing (n = 68), and genome-wide methylation profiling (n = 76). WES data from 24 patient tumors was compared with derivative models. Results: PDXs recapitulate many key phenotypic and molecular features of patient tumors. Orthotopic PDXs show characteristic tumor morphology and invasion patterns, but largely lack microvascular proliferation and necrosis. PDXs capture common and rare molecular drivers, including alterations of TERT, EGFR, PTEN, TP53, BRAF, and IDH1, most at frequencies comparable with human glioblastoma. However, PDGFRA amplification was absent. RNA-sequencing and genome-wide methylation profiling demonstrated broad representation of glioblastoma molecular subtypes. MGMT promoter methylation correlated with increased survival in response to temozolomide. WES of 24 matched patient tumors showed preservation of most genetic driver alterations, including EGFR amplification. However, in four patient–PDX pairs, driver alterations were gained or lost on engraftment, consistent with clonal selection. Conclusions: Our PDX panel captures the molecular heterogeneity of glioblastoma and recapitulates many salient genetic and phenotypic features. All models and genomic data are openly available to investigators.
Predictive and Precision Medicine with Genomic Data
Baudhuin, Linnea M. , Biesecker, Leslie G. , Burke, Wylie , Green, Eric D. , Green, Robert C.

Mayo Clinic

Clinical Chemistry | December 16, 2019 | Volume: 66 | Issue: 1 | Pages: 33-41

10.1373/clinchem.2019.304345 | PMID 31843866 Get It

Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families
Yang, Xin , Doroszuk, Alicja, Schneider, Sandra , Allen, Jamie , Decker, Brennan , Redman, James , Scarth, James A. , Plaskocinska, Inga, Luccarini, Craig , Shah, Mitul , Pooley, Karen A. , Dorling, Leila , Lee, Andrew , Adank, Muriel A. , Aittomäki, Kristiina, Andrulis, Irene L. , Ang, Peter , Bernstein, Jonine L. , Bobolis, Kristie, Borg, Åke , Blomqvist, Carl , Claes, Kathleen , Cuggia, Adeline , Culver, Julie O. , Damiola, Francesca , Pauw, Antoine De , Dolinsky, Jill S. , Engel, Christoph , Evans, D. Gareth , Goode, Ellen L. , Gruber, Stephen B., Hahnen, Eric , Hake, Christopher R., Heikkinen, Tuomas , Hurley, Judith , Janavičius, Ramūnas , Kleibl, Zdeněk , Kleiblová, Petra , Konstantopoulou, Irene , Kvist, Anders , LaDuca, Holly , Lee, Ann S. G. , Lesueur, Fabienne , Mannermaa, Arto, Manoukian, Siranoush , McFarland, Rachel, McKinnon, Wendy, Meindl, Alfons , Metcalfe, Kelly , Taib, Nur Aishah Mohd , Moilanen, Jukka S. , Nathanson, Katherine L. , Ng, Pei Sze , Nguyen‐Dumont, Tú , Nielsen, Sarah M. , Obermair, Florian , Offit, Kenneth, Olopade, Olufunmilayo I. , Ottini, Laura , Penkert, Judith , Pylkäs, Katri , Ramus, Susan J. , Rudaitis, Vilius , Side, Lucy, Silva‐Smith, Rachel , Silvestri, Valentina , Skytte, Anne‐Bine , Slavin, Thomas, Soukupová, Jana , Trainer, Alison H., Unzeitig, Gary, Usha, Lydia , Hansen, Thomas van Overeem , Whitworth, James , Wood, Marie , Yip, Cheng Har , Yoon, Sook‐Yee , Yussuf, Amal , Zogopoulos, George , Goldgar, David E. , Chenevix‐Trench, Georgia , George, Sophia , Houdayer, Claude , James, Paul A. , El-Haffaf, Zaki, Ehrencrona, Hans , Janatová, Markéta , Peterlongo, Paolo , Nevanlinna, Heli, Schmutzler, Rita K., Teo, Soo‐Hwang , Weitzel, Jeffrey N. , Elliott, Aaron , Winqvist, Robert , Easton, Douglas F. , Antoniou, Antonis C. , Houdayer, Claude , James, Paul , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Teo, Soo H , Weitzel, Jeffrey N , Claes, Kathleen B M , Ehrencrona, Hans , Evans, D Gareth , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Silvestri, Valentina , Nathanson, Katherine L , Engel, Christoph , Nguyen-Dumont, Tu , Chenevix-Trench, Georgia , Ottini, Laura , Metcalfe, Kelly A , Pylkäs, Katri , Janatova, Marketa , Soukupova, Jana , Hansen, Thomas van Overeem , Kleibl, Zdenek , Manoukian, Siranoush , Mohd Taib, Nur Aishah , Decker, Brennan , Leslie, Goska , Dunning, Alison M. , Adlard, Julian , Barwell, Julian , CONCANNON, PATRICK J. , Dı́ez, Orland , Domchek, Susan M. , Fostira, Florentia , Garber, Judy E. , Golmard, Lisa , Maher, Eamonn R. , Mannermaa, Arto, Meindl, Alfons , Neuhausen, Susan L. , Radice, Paolo , Slavin, Thomas P. , Tondini, Carlo Alberto , Hopper, John L. , Pharoah, Paul D.P. , Balmañà, Judith , El-Haffaf, Zaki, Nevanlinna, Heli , Robson, Mark E. , Pal, Tuya , Couch, Fergus J. , Southey, Melissa C. , Foulkes, William D. , Tischkowitz, Marc D.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2019 | Volume: 38 | Issue: 7 | Pages: 674-685

10.1200/jco.19.01907 | PMID 31841383 Get It

PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized.METHODSWe analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.RESULTSWe found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10−76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10−3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10−3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10−2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( P for trend = 2.0 × 10−3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.CONCLUSIONThese results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Manifestations of Skull Base IgG4‐Related Disease: A Multi‐Institutional Study
Marinelli, John P. , Marvisi, Chiara , Peters, Pierce A., Dowling, Eric M. , Palumbo, Alessandro , Lane, John I. , Appelbaum, Eric N. , Sweeney, Alex D. , Carlson, Matthew L. , Sweeney, Alex D , Carlson, Matthew L , Marvisi, Chiara , Vaglio, Augusto , Dowling, Eric M.

Mayo Clinic

The Laryngoscope | December 16, 2019 | Volume: 130 | Issue: 11 | Pages: 2574-2580

10.1002/lary.28478 | PMID 31841234 Get It

ObjectiveIgG4‐related disease (IgG4‐RD) is a recently recognized disease characterized by fibroinflammatory infiltrates rich in IgG4+ plasma cells that can present as isolated tumor‐like lesions of the head and neck. The objective of the current study was to describe the cranial base manifestations of IgG4‐RD.MethodsReview of all cases at three tertiary‐referral centers since disease description in 2003.ResultsEleven patients were identified at a median age at presentation of 58 years (IQR, 38–65; 55% male). Ten (91%) patients had isolated skull base masses without systemic disease. Cranial neuropathies were commonly observed in the abducens (45%), trigeminal (18%), and facial nerves (18%). Lesions frequently involved the cavernous sinus (55%; 6/11) with extension to the petroclival junction in 50% (3/6). Infiltration of the internal auditory canal was present in 27% (3/11) with one case demonstrating erosion of the bony labyrinth. Preliminary clinical diagnoses commonly included nasopharyngeal cancer, pituitary macroadenoma, cholesteatoma, and meningioma / multiple meningioma syndrome. Local biopsy demonstrated >30 IgG4‐positive plasma cells per high‐powered field or an IgG4:IgG ratio greater than 40% in all cases. Rapid and durable clinical improvement was seen in 91% following corticosteroid and rituximab therapy.ConclusionsIgG4‐RD nonspecifically presents as a rare cause of the skull base mass. Often presenting without concomitant systemic disease, local diagnostic biopsies are required. Obtaining adequate tissue specimen is complicated by densely fibrotic cranial base lesions that are frequently in close proximity to critical neurovascular structures. Primary medical therapy with corticosteroids and rituximab is effective in most patients.Level of Evidence4 Laryngoscope, 130:2574–2580, 2020
ASHP Guidelines on Pharmacy Services in Solid Organ Transplantation
Maldonado, Angela Q. , Hall, Reed C., Pilch, Nicole A. , Ensor, Christopher R. , Anders, S., Gilarde, Jennifer, Tichy, Eric M.

Mayo Clinic

American Journal of Health-System Pharmacy | December 13, 2019 | Volume: 77 | Issue: 3 | Pages: 222-232

10.1093/ajhp/zxz291 | PMID 31834928 Get It

Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Shrader, Peter, Pieper, Karen S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Go, Alan S. , Piccini, Jonathan P. , Patients, *On behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) I & II Investigators and, Freeman, James V. , Allen, Larry A. , Chan, Paul S. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Hylek, Elaine M. , Steinberg, Benjamin A. , Peterson, Eric D. , Patients, *On behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) I & II Investigators and

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 13, 2019 | Volume: 12 | Issue: 12 | Pages: No page available

10.1161/circep.119.007612 | PMID 31830822 Get It

Background: Studies evaluating the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outcomes have shown mixed results. In addition, guidelines recommend continuing oral anticoagulation (OAC) after ablation for those at risk of stroke, but real-world data are lacking. Methods: We evaluated outcomes including death, myocardial infarction, stroke or systemic embolism, intracranial bleeding, major bleeding, and hospitalization in patients undergoing AF ablation compared with a propensity score matched cohort of patients treated with anti-arrhythmic medications only in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation registries. Cox proportional hazards regression was performed to evaluate the association between AF ablation and outcomes. We then evaluated patterns of treatment with OAC among AF ablation patients. Results: Among 21 595 patients, 1190 (6%) underwent de novo AF ablation. Our propensity score-matched cohort included 1087 patients who underwent AF ablation matched 1:1 with 1087 patients treated with antiarrhythmic medications only. There were no significant differences in the risk of all-cause and cardiovascular death, and most other major adverse cardiovascular and neurological events. AF catheter ablation was associated with an increased risk of all-cause hospitalization during follow-up (hazard ratio, 1.24 [95% CI, 1.05–1.46]), particularly in the first 3 months (the standard blanking period) after the procedure. Among those who underwent AF ablation with a CHA 2 DS 2 VASc score ≥2 for men and ≥3 for women, 23% had OAC discontinued after ablation. Among those who discontinued OAC, the median time to discontinuation was 6.2 months. Conclusions: In this large US national registry, we found no difference in adjusted rates of cardiovascular or all-cause death between patients treated with AF catheter ablation and antiarrhythmic medications only. Notably, discontinuation of OAC after ablation remains relatively common despite guideline recommendations for continued stroke prevention therapy in patients at risk of stroke.
3-Dimensionally Printed Biomimetic Surgical Simulation—Operative Technique of a Transforaminal Lumbar Interbody Fusion: 2-Dimensional Operative Video
Clifton, William , Damon, Aaron , Nottmeier, Eric W. , Pichelmann, Mark A., Nottmeier, Eric, Pichelmann, Mark, Clifton, William E

Mayo Clinic

Operative Neurosurgery | December 12, 2019 | Volume: 19 | Issue: 2 | Pages: E153-E153

10.1093/ons/opz398 | PMID 31828347 Get It

Abstract We present a surgical video highlighting the technical demonstration and microsurgical anatomy of an L4-5 transforaminal lumbar interbody fusion utilizing a combination of thermoplastic polymers and 3-dimensional printing technology to create a biomimetic lumbar spine surgical simulator. The posterior elements of L4-5 and the inferior portion of L3 are exposed in their entirety, including the transverse processes in order to identify the appropriate landmarks for pedicle screw insertion. The interspinous ligament of L4-5 is removed, and an interlaminar spreader is used to distract the facet joint. An inferior L4 facetectomy is performed for local autograft harvesting. The L4 and L5 pedicles are skeletonized to completely open the foramen in order to ensure that the exiting nerve root will not be compromised during cage insertion. The ligamentum flavum is then removed, exposing the common thecal sac and L5 traversing root. The L4 exiting nerve root is then identified, completing Kambin's triangle and location of the disc space. The disc is incised, and a combination of punches and curettes are used to completely remove the disc. After an interbody trial is used to assess the proper cage size, the cage is packed with graft and inserted into the midline of the disc space. Pedicle screws are then placed using an anatomic freehand technique, and intraoperative fluoroscopy is performed in order to evaluate the instrumentation and interbody position. If a contralateral decompression is required, a facet-sparing technique is performed in order to preserve bony surface for the fusion. Patient consent was not required for this simulation video.
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations
Kotwal, Anupam , Kumar, Rajiv , Murthy, Vishakantha , Schultz‐Rogers, Laura , Zimmermann, Michael T. , Lanpher, Brendan C. , Stabach, Paul R., Klee, Eric W. , Braddock, Demetrios T. , Wermers, Robert A. , Schultz-Rogers, Laura, Lanpher, Brendan, Klee, Eric, Braddock, Demetrios T , Kudva, Yogish C , Zimmermann, Michael T , Kumar, Rajiv , Ferrer, Alejandro , Singh, Ravinder , Savill, Kristin M. Zimmerman

Mayo Clinic

Journal of Bone and Mineral Research | December 11, 2019 | Volume: 35 | Issue: 4 | Pages: 662-670

10.1002/jbmr.3938 | PMID 31826312 Get It

ABSTRACT Inactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal-recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54-year-old female with biallelic mutation of ENPP1, c.323G &gt; T; p.Cys108Phe and c.1441C &gt; T; p.Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation, which was not previously reported, was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multigland parathyroidectomy, increased carotid intima-media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C-terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism, which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation. © 2019 American Society for Bone and Mineral Research.
Acute airway compromise after recombinant human TSH administration: A case report and review of the literature
Dowling, Eric M. , Kasperbauer, Jan L. , Bayan, Semirra L. , Dowling, Eric , Kasperbauer, Jan , Bayan, Semirra, Bayan, Semirra , Morris, John

Mayo Clinic

The Laryngoscope | December 10, 2019 | Volume: 130 | Issue: 11 | Pages: 2725-2727

10.1002/lary.28439 | PMID 31821556 Get It

Radioiodine ablation is a commonly utilized treatment for differentiated thyroid carcinoma. Uptake of radioiodine can be enhanced by pretreatment with thyroid hormone withdrawal or administration of recombinant human thyroid‐stimulating hormone (rhTSH). rhTSH is generally well‐tolerated with minimal adverse effects. However, in patients with extensive tumor burden in confined anatomic spaces, rapid enlargement of normal or neoplastic thyroid tissue secondary to rhTSH administration can result in significant compressive effects. In this report, we describe a case of rapid airway deterioration requiring intubation in a patient with involvement of the thyroid cartilage by papillary thyroid carcinoma.Laryngoscope, 122:0000–0000, 2019 Laryngoscope, 130:2725–2727, 2020